For patients under 65 with CAP and no comorbidities, which is a reasonable first-line outpatient therapy?

• A. Ceftriaxone
• B. Azithromycin monotherapy
• C. Levofloxacin
• D. Amoxicillin

Answer: (D)

In healthy adults with community-acquired pneumonia who aren’t at risk for resistant pathogens, the aim is to treat the most likely organism with an oral, well-tolerated, inexpensive antibiotic while avoiding unnecessary broad-spectrum therapy. Amoxicillin fits this role well because it provides reliable coverage against Streptococcus pneumoniae, the most common cause of CAP in this group, and it’s easily taken by mouth. This makes it a convenient and appropriate first-line option for outpatient management in someone under 65 with no comorbidities.

Ceftriaxone would be used in more severe cases or when inpatient care is needed, since it’s given by injection and not suited for simple outpatient therapy. Levofloxacin offers broad coverage, including atypicals, but its use as a first-line outpatient agent is limited by higher risks of adverse effects and the push to avoid broad-spectrum antibiotics when a narrower option suffices. Azithromycin monotherapy targets atypicals and pneumococcus, but rising macrolide resistance among Streptococcus pneumoniae reduces its reliability as a sole agent in many communities, making amoxicillin the more dependable first-line choice in this scenario.